Xuanzhu Biopharm Co Ltd (2575) fair value: what the stock is really worth
As of Oct 2, 2026: fair value of Xuanzhu Biopharm Co Ltd HK$1.41, price HK$8.78, upside -83.9%, quality 57 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Xuanzhu Biopharm Co Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
Xuanzhu Biopharmaceutical Co., Ltd. engages in the development, industrialization, and commercialization of small-molecule chemical drugs and macromolecular biopharmaceuticals in China.
Show more
Xuanzhu Biopharmaceutical Co., Ltd. engages in the development, industrialization, and commercialization of small-molecule chemical drugs and macromolecular biopharmaceuticals in China. Its lead product candidates include Core- KBP-3571 for the treatment of duodenum ulcers; XZP-3287, a CDK4/6 inhibitor for the treatment of HR+/HER2 advanced breast cancer; and XZP-3621, a first-line treatment for patients with anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer. The company also develops KM501, a first-in-class HER2/HER2 bispecific antibody drug conjugate, which is in Phase I clinical trial; KM602, which is in Phase I clinical trial for anti-tumor; XZP-7797, a selective and brain-penetrating poly ADP-ribose polymerase 1 inhibitor; and XZP-6924, a ubiquitin-specific protease 1 (USP1) inhibitor. In addition, it develops XZB-0004, an oral small molecule anexelekto inhibitor; XZP-6877, a DNA-dependent protein kinase inhibitor; NG-350A, a next-generation oncolytic viral therapy; XZP-5610, a non-steroid farnesoid X receptor; and XZP-6019, a first-in-class ketohexokinase (KHK) inhibitor. The company was founded in 2008 and is headquartered in Beijing, China. Xuanzhu Biopharmaceutical Co., Ltd. is a former subsidiary of Sihuan Pharmaceutical Holdings Group Ltd.
Stock analysis
Xuanzhu Biopharm Co Ltd (2575) currently trades at HK$8.78, while our model-based Fair Value estimate is HK$1.41, 83.9% below the price, so the stock looks overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 87/100, which puts the evidence level at low.
Scenario range: HK$0.9300 (bear) to HK$1.77 (bull), the price of HK$8.78 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 57/100 (solid quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Xuanzhu Biopharm Co Ltd reported revenue of 56.1M CNY in FY2025 versus 32.0K CNY in FY2023, a compound +4,085.9%/yr. Reported net income was −266M CNY in FY2025.
Our AI-assisted moat analysis scores the competitive advantage at 35 out of 100 (low confidence).
What moves the price
The share trades about 89% below its 52-week high and 8% above its 52-week low.
For context, the median of 10 Healthcare peers we cover trades at −19% fair-value upside, at −84%, 2575 screens richer than that median.
Fair Value models
Bear HK$0.9300Fair Value HK$1.41Bull HK$1.77
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.44/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Compare Xuanzhu Biopharm Co Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 599 stocks
Beats the industry median on 3/6 measures
A mixed picture versus its industry peers.
Valuation
Quality Score56 · Above median
Fair Value upside−83.9% · Bottom 25%
Profitability
Return on assets−10.3% · Bottom 25%
Growth and dividend
Revenue growth140.9% · Top 25%
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
P/B0.60× · Cheapest 25%
P/S (TTM)17.76× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 17
FUTURE (revenue growth)100· sector 24
PAST (return on equity)0· sector 27
HEALTH (low debt)0· sector 96
DIVIDEND (yield)0· sector 30
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Xuanzhu Biopharm Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/2575
Frequently asked questions
Is Xuanzhu Biopharm Co Ltd (2575) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of HK$1.41 versus a price of HK$8.78, about −84% upside (overvalued).
What is the fair value of 2575?
Our model-based fair value for Xuanzhu Biopharm Co Ltd is HK$1.41 (as of Sep 24, 2026), built from audited fundamentals. The current price: HK$8.78.
What is the quality score of 2575?
Xuanzhu Biopharm Co Ltd has a Quality Score of 57/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Xuanzhu Biopharm Co Ltd (2575)?
Our model-based price target is the fair value of HK$1.41 (as of Sep 24, 2026) from 1 valuation models. Cautious scenario HK$0.9300, optimistic scenario HK$1.77. It is a calculation from audited fundamentals, not an analyst target.
What is the Xuanzhu Biopharm Co Ltd stock forecast for 2026?
Our models put fair value at HK$1.41, about −84% upside versus a price of HK$8.78 (overvalued). Cautious scenario HK$0.9300, optimistic scenario HK$1.77. The calculation is refreshed regularly with new filings.
What is the revenue of Xuanzhu Biopharm Co Ltd (2575)?
Xuanzhu Biopharm Co Ltd reported trailing-twelve-month revenue of about 51.8M CNY (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of Xuanzhu Biopharm Co Ltd (2575)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Xuanzhu Biopharm Co Ltd it is HK$1.41 per share (as of Sep 24, 2026), against a price of HK$8.78. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Xuanzhu Biopharm Co Ltd stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 2575 trades above its calculated fair value: price HK$8.78, fair value HK$1.41, a gap of about −84% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 2575?
No. The price is what the market pays today (HK$8.78); the fair value is what the company's own numbers justify (HK$1.41). For Xuanzhu Biopharm Co Ltd the two are HK$7.37 per share apart. That gap is exactly why we show both numbers side by side.
How much is Xuanzhu Biopharm Co Ltd worth?
The market values Xuanzhu Biopharm Co Ltd at about HK$7.2B (market capitalisation, as of Sep 24, 2026). Per share that is HK$8.78; our models calculate a fair value of HK$1.41 per share.
What do the bullish and bearish scenarios say about 2575?
Our models span a range for Xuanzhu Biopharm Co Ltd: cautious scenario HK$0.9300, base HK$1.41, optimistic HK$1.77 per share (as of Sep 24, 2026, price HK$8.78). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Xuanzhu Biopharm Co Ltd (2575)?
Balance-sheet figures for Xuanzhu Biopharm Co Ltd (as of Sep 24, 2026): return on equity −21.1%. They feed the Quality Score of 57/100, which measures business quality independently of the share price.
How far is 2575 from its 52-week high?
Xuanzhu Biopharm Co Ltd trades at HK$8.78, about 89% below its 52-week high of HK$82.95 and 8% above the low of HK$8.10 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of HK$1.41 is for.
Which stocks are comparable to Xuanzhu Biopharm Co Ltd?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Xuanzhu Biopharm Co Ltd stock attractive at the current price?
The data as of Sep 24, 2026: price HK$8.78, calculated fair value HK$1.41 (−84%), Quality Score 57/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 2575 calculated?
We run Xuanzhu Biopharm Co Ltd through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of HK$1.41, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Xuanzhu Biopharm Co Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Xuanzhu Biopharm Co Ltd (2575)?
The closing price on Oct 2, 2026 was HK$8.78. Our model-based fair value is HK$1.41, about −84% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Xuanzhu Biopharm Co Ltd right now?
The price sits above even our optimistic bull case (HK$1.77). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (57/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (HK$0.9300 to HK$1.77) leaves room in how you read the outcome.
Key figures of Xuanzhu Biopharm Co Ltd
How large is the market capitalisation of Xuanzhu Biopharm Co Ltd (2575)?
The market capitalisation of Xuanzhu Biopharm Co Ltd is HK$7.2B (≈ $920M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Xuanzhu Biopharm Co Ltd (2575)?
Earnings per share at Xuanzhu Biopharm Co Ltd are HK$−0.2500. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Xuanzhu Biopharm Co Ltd (2575)?
The return on equity (ROE) of Xuanzhu Biopharm Co Ltd is −21.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Xuanzhu Biopharm Co Ltd (2575)?
On an EBIT basis the return on assets of Xuanzhu Biopharm Co Ltd is −30.8% (avg 4y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Xuanzhu Biopharm Co Ltd (2575)?
The operating margin of Xuanzhu Biopharm Co Ltd is −350% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Xuanzhu Biopharm Co Ltd (2575)?
Revenue at Xuanzhu Biopharm Co Ltd is growing +141% versus a year earlier. How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Xuanzhu Biopharm Co Ltd (2575) generate?
The free cash flow of Xuanzhu Biopharm Co Ltd is −224M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Xuanzhu Biopharm Co Ltd (2575) hold?
Xuanzhu Biopharm Co Ltd holds more cash than debt, 765M CNY net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Xuanzhu Biopharm Co Ltd in the live analysis
One click puts Xuanzhu Biopharm Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
